Drug Profile
Research programme: PEGylated cytokines - Synageva
Alternative Names: AES-082; AES-091; SBC-091Latest Information Update: 07 Feb 2011
Price :
$50
*
At a glance
- Originator Synageva BioPharma
- Class Cytokines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Cancer; Infections
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 07 Feb 2011 No development reported - Preclinical for Cancer in USA (Parenteral)
- 07 Feb 2011 No development reported - Preclinical for Infections in USA (Parenteral)
- 03 Oct 2008 PEGylated cytokine programme is available for licensing and/or co-development in the USA (http://www.synageva.com)